GLYRX-PF Drug Patent Profile
✉ Email this page to a colleague
When do Glyrx-pf patents expire, and when can generic versions of Glyrx-pf launch?
Glyrx-pf is a drug marketed by Exela Pharma and is included in one NDA.
The generic ingredient in GLYRX-PF is glycopyrrolate. There are seventeen drug master file entries for this compound. Fifty-five suppliers are listed for this compound. Additional details are available on the glycopyrrolate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Glyrx-pf
A generic version of GLYRX-PF was approved as glycopyrrolate by AM REGENT on July 23rd, 1986.
Summary for GLYRX-PF
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 26 |
Patent Applications: | 16 |
Formulation / Manufacturing: | see details |
Drug Prices: | Drug price information for GLYRX-PF |
What excipients (inactive ingredients) are in GLYRX-PF? | GLYRX-PF excipients list |
DailyMed Link: | GLYRX-PF at DailyMed |
Pharmacology for GLYRX-PF
Drug Class | Anticholinergic |
Mechanism of Action | Cholinergic Antagonists |
US Patents and Regulatory Information for GLYRX-PF
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Exela Pharma | GLYRX-PF | glycopyrrolate | SOLUTION;INTRAMUSCULAR, INTRAVENOUS | 210997-001 | Jul 11, 2018 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Exela Pharma | GLYRX-PF | glycopyrrolate | SOLUTION;INTRAMUSCULAR, INTRAVENOUS | 210997-003 | Apr 9, 2020 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Exela Pharma | GLYRX-PF | glycopyrrolate | SOLUTION;INTRAMUSCULAR, INTRAVENOUS | 210997-002 | Jul 11, 2018 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Exela Pharma | GLYRX-PF | glycopyrrolate | SOLUTION;INTRAMUSCULAR, INTRAVENOUS | 210997-004 | Dec 14, 2020 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |